Chen Y, Byrne JA (2017). Tumor protein D52. In: Encyclopaedia of Signalling Molecules, 2nd edition. Choi S (Ed.), Springer, in press.
Ling R, Rush A, Carpenter J, Carter C, Watson P, Byrne JA, Searles A (2017). An Australian biobank certification scheme: a study of economic costs to participating biobanks. Biopreserv Biobank, in press.
Saletta F, Vilain RE, Gupta AK, Nagabushan S, Yuksal A, Catchpoole D, Scolyer R, Byrne JA, McCowage G (2017). PD-L1 expression in a large cohort of pediatric solid tumor patients and association with clinico-pathological features in neuroblastoma. JCO Precision Med. 1: 1-12.
Chen Y, Frost S, Byrne JA (2016). Dropping in on the lipid droplet- tumor protein D52 (TPD52) as a new regulator and resident protein. Adipocyte 5: 326-32.
Rush A, Byrne JA (2016). Quality and reporting practices in an Australian cancer biobank cohort. Clin Biochem 49: 492-7.
Kamili A, Roslan N, Frost S, Cantrill LC, Wang D, Della-Franca A, Bright RK, Groblewski GE, Straub BK, Hoy AJ, Chen Y, Byrne JA (2015). TPD52 expression increases neutral lipid storage within cultured cells. J Cell Sci 128: 3223-38.
Rush A, Christiansen JH, Farrell JP, Goode SM, Scott RJ, Spring KS, Byrne JA (2015). Biobank classification in an Australian setting. Biopreserv Biobank 13: 212-8.
Saletta F, Dalla Pozza L, Byrne JA (2015). Genetic causes of cancer predisposition in children and adolescents. Trans Pediatrics 4: 67-75.
Byrne JA, Frost S, Chen Y, Bright RK (2014). Tumor protein D52 (TPD52) and cancer – oncogene understudy, or understudied oncogene? Tumour Biol 35: 7369-82.
Saletta F, Wadham C, Ziegler DS, Marshall GM, Haber M, McCowage G, Norris MD, Byrne JA (2014). Molecular profiling of childhood cancer: biomarkers and novel therapies. BBA Clinical 1: 59-77